Business Description
Dynavax Technologies Corp
NAICS : 325412
SIC : 2834
ISIN : US2681582019
Share Class Description:
DVAX: Ordinary SharesDescription
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.05 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.37 | |||||
| Debt-to-EBITDA | 6.43 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.73 | |||||
| Beneish M-Score | -1.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 57.8 | |||||
| 3-Year Book Growth Rate | 108.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 188.97 | |||||
| Future 3-5Y Total Revenue Growth Rate | 18.38 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.35 | |||||
| 9-Day RSI | 61.96 | |||||
| 14-Day RSI | 60.51 | |||||
| 6-1 Month Momentum % | -5.97 | |||||
| 12-1 Month Momentum % | -21.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.23 | |||||
| Quick Ratio | 12.34 | |||||
| Cash Ratio | 10.91 | |||||
| Days Inventory | 472.32 | |||||
| Days Sales Outstanding | 74.48 | |||||
| Days Payable | 36.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.5 | |||||
| Shareholder Yield % | 0.33 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.85 | |||||
| Operating Margin % | -4.21 | |||||
| Net Margin % | 7.85 | |||||
| FCF Margin % | 8.69 | |||||
| ROE % | 3.23 | |||||
| ROA % | 2.03 | |||||
| ROIC % | -4.35 | |||||
| ROC (Joel Greenblatt) % | 23.34 | |||||
| ROCE % | 3.27 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 99.31 | |||||
| Forward PE Ratio | 50.83 | |||||
| PE Ratio without NRI | 99.31 | |||||
| PS Ratio | 7.13 | |||||
| PB Ratio | 2.49 | |||||
| Price-to-Tangible-Book | 2.5 | |||||
| Price-to-Free-Cash-Flow | 92.21 | |||||
| Price-to-Operating-Cash-Flow | 74.62 | |||||
| EV-to-EBIT | 37.13 | |||||
| EV-to-EBITDA | 29.56 | |||||
| EV-to-Revenue | 4.41 | |||||
| EV-to-Forward-Revenue | 3.58 | |||||
| EV-to-FCF | 50.75 | |||||
| Price-to-Projected-FCF | 2.14 | |||||
| Price-to-Median-PS-Value | 0.42 | |||||
| Price-to-Graham-Number | 3.32 | |||||
| Price-to-Net-Current-Asset-Value | 3.11 | |||||
| Price-to-Net-Cash | 4.42 | |||||
| Earnings Yield (Greenblatt) % | 2.69 | |||||
| FCF Yield % | 1.34 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DVAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dynavax Technologies Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 260.811 | ||
| EPS (TTM) ($) | 0.13 | ||
| Beta | 0.9 | ||
| Volatility % | 16.2 | ||
| 14-Day RSI | 60.51 | ||
| 14-Day ATR ($) | 0.468252 | ||
| 20-Day SMA ($) | 12.487 | ||
| 12-1 Month Momentum % | -21.42 | ||
| 52-Week Range ($) | 9.74 - 15.01 | ||
| Shares Outstanding (Mil) | 131.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dynavax Technologies Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dynavax Technologies Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dynavax Technologies Corp Frequently Asked Questions
What is Dynavax Technologies Corp(DVAX)'s stock price today?
The current price of DVAX is $12.91. The 52 week high of DVAX is $15.01 and 52 week low is $9.74.
When is next earnings date of Dynavax Technologies Corp(DVAX)?
The next earnings date of Dynavax Technologies Corp(DVAX) is 2025-02-21 Est..
Does Dynavax Technologies Corp(DVAX) pay dividends? If so, how much?
Dynavax Technologies Corp(DVAX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers